Sengul, AysunMutlu, PinarOzdemir, OzerSatici, CelalTuran, Muzaffer OnurArslan, SertacOgang, NalanUnsal, Zuhal EkiciBozkus, FulsenCapraz, AylinDemirkol, Mustafa AsimMutlu, Levent CernGulhanm, Pinar YildizAlkilinc, ErsinFazlioglu, NevinSoyler, YaseminKabalak, Pinar AkinKizilgoz, DeryaTuran, Pakize AyseYildirim, FatmaAydemir, YusufSen, NazanMirici, Arzu2022-12-212022-12-2120221747-6348http://hdl.handle.net/11727/8389Background COVID-19 is a disease associated with diffuse lung injury that has no proven effective treatment yet. It is thought that glucocorticoids may reduce inflammation-mediated lung injury, disease progression, and mortality. We aimed to evaluate our patient's characteristics and treatment outcomes who received corticosteroids for COVID-19 pneumonia. Methods We conducted a multicenter retrospective study and reviewed 517 patients admitted due to COVID-19 pneumonia who were hypoxemic and administered steroids regarding demographic, laboratory, and radiological characteristics, treatment response, and mortality-associated factors. Results Of our 517 patients with COVID-19 pneumonia who were hypoxemic and received corticosteroids, the mortality rate was 24.4% (n = 126). The evaluation of mortality-associated factors revealed that age, comorbidities, a CURB-65 score of >= 2, higher SOFA scores, presence of MAS, high doses of steroids, type of steroids, COVID-19 treatment, stay in the intensive care unit, high levels of d-dimer, CRP, ferritin, and troponin, and renal dysfunction were associated with mortality. Conclusion Due to high starting and average steroid doses are more associated with mortality, high-dose steroid administration should be avoided. We believe that knowing the factors associated with mortality in these cases is essential for close follow-up. The use of CURB-65 and SOFA scores can predict prognosis in COVID-19 pneumonia.enginfo:eu-repo/semantics/closedAccessCOVID-19corticosteroidhypoxemiamortalityprognosisarticle1689539580008311577000012-s2.0-85135114550